Results 21 to 30 of about 30,834 (256)
Efficacy of Rubella Vaccination after Co-Inoculation with Rhogam
Viruses, 2023 Congenital rubella syndrome is a constellation of birth defects that can have devastating consequences, impacting approximately 100,000 births worldwide each year. The incidence is much lower in countries that routinely vaccinate their population. In the
Joshua S. Brunton +5 more
doaj +1 more source
Mitigating Vaccine Hesitancy and Building Trust to Prevent Future Measles Outbreaks in England
Vaccines, 2023 Measles, a highly infectious respiratory viral infection associated with severe morbidity and mortality, is preventable when coverage with the highly effective measles, mumps and rubella vaccine (MMR) is ≥95%. Vaccine hesitancy is responsible for measles
Sarah Thompson +3 more
doaj +1 more source
A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
Molecular Therapy: Oncolytics, 2022 Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. The intratumoral administration of these repurposed vaccines can induce immune cell infiltration into the treated tumor. Here, we have used an approved trivalent live
Manlio Fusciello +10 more
doaj +1 more source
Archives of Disease in Childhood, 2000 Live measles and mumps vaccine viruses are cultured in chick embryo fibroblasts and may contain minute amounts of egg related antigens.1-3 In view of this, there has been a longstanding debate on the safety of these vaccines in children with severe allergic reactions to egg. Initially it was believed that such children could safely receive the vaccine;
R, Lakshman, A, Finn
openaire +2 more sources
Vaccines, 2022 Cross-protection from previous live attenuated vaccines is proposed to explain the low impact of COVID-19 on children. This study aimed to evaluate the effect of live attenuated MMR vaccines on the risk of being hospitalized for COVID-19 in children.
Epiphane Kolla +5 more
doaj +1 more source
Determination of ELISA reactive mumps IgG antibodies in MMR vaccine recipients in comparison with MMR vaccine naive children: A cross sectional study [PDF]
Scripta Medica, 2021 Background/Aim: Mumps is by vaccine preventable infectious disease characterised by parotitis. In India mumps vaccines are not currently used under National Immunisation Programme (NIP).
Gupta Riya, Saxena Naveen, Gupta Parul
doaj +1 more source
Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
mBio, 2020 The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against coronavirus disease 2019 (COVID-19). Our aim was to determine whether any MMR IgG titers are inversely correlated with severity in recovered COVID-19 patients ...
Jeffrey E. Gold +9 more
doaj +1 more source
Memorias do Instituto Oswaldo Cruz, 2019 BACKGROUND Field testing required to license the combined measles, mumps, and rubella (MMR) vaccine must take into account the current recommendation of the vaccine in Brazil: first dose at 12 months and second dose at 15 months of age in combination ...
Eliane Matos dos Santos +12 more
doaj +1 more source
Characteristics of 5-year-olds who catch-up with MMR: findings from the UK Millennium Cohort Study [PDF]
, 2013 Objectives To examine predictors of partial and full measles, mumps and rubella (MMR) vaccination catch-up between 3 and 5 years. Design Secondary data analysis of the nationally representative Millennium Cohort Study (MCS).
Bedford, Helen +3 more
core +2 more sources